One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology | Zendy

Wieland D Müskens | Zendy; Sanne A A Rongen-van Dartel | Zendy; Steven Teerenstra | Zendy; Eddy Adang | Zendy; Piet L. C. M. van Riel | Zendy

Open Access

One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology

Author(s) -

Wieland D Müskens,

Sanne A A Rongen-van Dartel,

Steven Teerenstra,

Eddy Adang,

Piet L. C. M. van Riel

Publication year - 2020

Publication title -

rheumatology advances in practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.539

H-Index - 4

ISSN - 2514-1775

DOI - 10.1093/rap/rkaa042

Subject(s) - etanercept , medicine , discontinuation , nocebo effect , cohort , retention rate , biosimilar , rheumatology , hazard ratio , proportional hazards model , rheumatoid arthritis , placebo , confidence interval , alternative medicine , pathology , computer security , computer science

Non-mandatory transition from etanercept originator to its biosimilar using an opt-in approach in a setting promoting shared decision-making resulted in a higher discontinuation of etanercept compared with the historical cohort. This could be attributed largely to the nocebo effect.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research